Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Large Drop in Short Interest

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 351,459 shares, a decline of 43.4% from the August 31st total of 620,909 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 36 shares, the days-to-cover ratio is currently 9,762.8 days.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Finally, Pareto Securities cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

Get Swedish Orphan Biovitrum alerts:

View Our Latest Stock Report on Swedish Orphan Biovitrum

Swedish Orphan Biovitrum Stock Performance

BIOVF remained flat at $42.90 during trading on Thursday. 150 shares of the company’s stock were exchanged, compared to its average volume of 22. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20. Swedish Orphan Biovitrum has a twelve month low of $33.30 and a twelve month high of $49.03. The business’s 50-day simple moving average is $48.00 and its two-hundred day simple moving average is $46.20. The stock has a market capitalization of $15.27 billion, a P/E ratio of 95.34 and a beta of 0.33.

Swedish Orphan Biovitrum Company Profile

(Get Free Report)

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing treatments for rare diseases. Its activities center on conditions in hematology, immunology and specialty care, where patients often have limited treatment options.

Sobi’s portfolio includes therapies for hemophilia and other bleeding disorders, immune-mediated diseases, and rare inflammatory or hematologic conditions. Its products include Elocta and Alprolix for hemophilia, Doptelet for certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for paroxysmal nocturnal hemoglobinuria.

Featured Stories

• Five stocks we like better than Swedish Orphan Biovitrum
• JPMorgan Bets on Genius Sports as the Market Loses Patience
• Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
• First Watch’s Growth Story Meets a Reality Check
• Down 50% and Climbing Again: 3 AI Stocks Rebuilding After Brutal Pullbacks

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.